Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Inv. presentation
Eloxx Pharmaceuticals, Inc. (ELOX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update"
11/14/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/04/2022 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update"
11/09/2021 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update"
08/16/2021 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update"
05/06/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/05/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update"
08/07/2019 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results and Provides Business Update"
05/09/2019 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results and Provides Business Update"
11/08/2018 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Third Quarter 2018 Financial and Operating Results and Provides Business Update"
08/07/2018 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update"
05/10/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 10, 2018 Eloxx Pharmaceuticals, Inc. Delaware 001-31326 84-1368850 950 Winter Street Waltham, MA 02451 Registrant's telephone number, including area code: 577-5300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communicati...",
"Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Update"
03/19/2018 8-K Investor presentation, Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update",
"Presentation of the Company"
11/17/2015 8-K Quarterly results
Docs: "Sevion Therapeutics Reports First Quarter 2016 Financial Results"
05/15/2015 8-K Quarterly results
Docs: "SEVION THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS"
02/18/2015 8-K Quarterly results
Docs: "Sevion Therapeutics Reports Second Quarter 2015 Financial Results San Diego, CA – February 18, 2014 - Sevion Therapeutics, Inc. , a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal quarter ended December 31, 2014 . Sevion has been advancing its SVN001 product candidate through preclinical development where it has demonstrated potent activity as well as advancing its SVN002 product candidate through preclinical development. However, given the Company’ s limited capital resources, in December 2014, the Company decided to temporarily reduce its research and development spending on its antibody program until it is able to consummate a strategic trans..."
11/17/2014 8-K Quarterly results
Docs: "Sevion Therapeutics Reports First Quarter 2015 Financial Results Bridgewater, NJ - November 17, 2014 - Sevion Therapeutics, Inc. , a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal quarter ended September 30, 2014 . "During the first fiscal quarter of 2015, we made a strategic decision to focus our efforts and resources on our proprietary antibody discovery technology platforms, including two promising antibodies that are advancing toward IND status,” said Ronald Martell, Chief Executive Officer of Sevion. “Our strategy for building long-term shareholder value is to leverage our pipeline and platforms through partnerships, while looking at high-..."
05/16/2013 8-K Quarterly results
Docs: "Joel Brooks Heather Branham Chief Financial Officer 908-393-9393 Leslie J. Browne, Ph.D."
02/15/2013 8-K Quarterly results
Docs: "Joel Brooks Heather Branham"
11/15/2012 8-K Quarterly results
Docs: "Senesco Technologies Reports First Quarter Fiscal 2013 Financial Results BRIDGEWATER, N.J. – Senesco Technologies, Inc. today reported financial results for the first quarter of fiscal year 2013 which ended on September 30, 2012. Highlights of the first quarter and recent weeks include: · The Company expanded its Phase 1b/2a clinical trial to include Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma. · The Company dosed the first Diffuse Large B-Cell Lymphoma patient. · The Company began dosing patients in the second cohort at the next higher dose level in its Phase 1b/2a clinical trial for the treatment of multiple myeloma. · The Company completed the first cohort of patients in its Phase 1b/2a clinical trial for the treatment of multiple myeloma in which..."
05/15/2012 8-K Form 8-K - Current report
02/15/2012 8-K Quarterly results
Docs: "Senesco Technologies Reports Second Quarter Fiscal 2012 Financial Results"
11/15/2011 8-K Form 8-K - Current report
05/16/2011 8-K Form 8-K - Current report
02/10/2011 8-K Form 8-K - Current report
11/15/2010 8-K Form 8-K - Current report
05/16/2007 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy